Europe Natural Killer (NK) Cell Therapeutics Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Nov 2020
  • Europe
  • 350 Pages
  • No of Tables: 142
  • No of Figures: 40

Europe Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases and Others), End User (Hospitals, Specialty Clinics and Research & Academic Institutes), Distribution Channel (Hospital Pharmacies, Direct Tender and Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg and Rest of Europe), Industry Trends and Forecast to 2027

Europe Natural Killer (NK) Cell Therapeutics Market Market Analysis and Insights : Europe Natural Killer (NK) Cell Therapeutics Market

Europe Natural Killer (NK) Cell therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 40.7% in the forecast period of 2020 to 2027 and is expected to reach USD 202.89 million by 2027.

Increase in patient population with chronic diseases and adoption of natural killer (NK) cell therapy in emerging markets are the major drivers which propelled the demand of the market in the forecast period.

Natural killer (NK) cell therapeutics comprises features such increasing need for better therapeutics options will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing investment in research and development leads to the market growth.

Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative Natural Killer (NK) Cell therapeutics which is expected to provide various other opportunities in the Natural Killer (NK) Cell therapeutics market. However, adverse side effects of therapies and availability of alternatives for tumor treatment expected to restraint the market growth in the forecast period.

The natural killer (NK) cell therapeutics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Natural Killer (NK) Cell Therapeutics Market Europe Natural Killer (NK) Cell Therapeutics Market Scope and Market Size

Europe natural killer (NK) cell therapeutics market is categorized into five notable segments which are based on therapeutics, approaches, application, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of therapeutics, the Europe natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies. In 2020, NK cell therapies segment is dominating the market as Natural Killer (NK) Cell are innate cytotoxic lymphocytes and are under extensive research for tumor treatment.
  • On the basis of approaches, the Europe natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies. In 2020, antibody-dependent cell-mediated cytotoxicity (ADCC) segment is dominating the market as are off-the-shelf approach used for activation of natural killer cells. Moreover increasing need of novel – immune- oncology approach is acting as another factor for market growth.
  • On the basis of application, the Europe natural killer (NK) cell therapeutics market is segmented into cancer, immunoproliferative disorders, acute infectious diseases, gastrointestinal diseases and others. In 2020, cancer segment is dominating the market as NK cell therapies have been proved to have highest efficacy for treatment of cancer cells that lacks MHC I molecule.
  • On the basis of end user, the Europe natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics and research & academic institutes. In 2020, hospitals segment is dominating the market as advanced diagnostic tools are present in hospitals for disease diagnosis. Moreover clinical trials for NK cell therapies are conducted at hospitals.
  • On the basis of distribution channel, the Europe natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender and others. In 2020, hospital pharmacies segment is dominating the market as most patients who used to visit hospitals for achieving effective treatment against several kinds of disease procures medicines from hospital pharmacies.

Natural Killer (NK) Cell Therapeutics Market Country Level Analysis

The natural killer (NK) cell therapeutics market is analyzed and market size information is provided into five notable segments which are based on therapeutics, approaches, application, end-user and distribution channel.

The countries covered in the natural killer (NK) cell therapeutics market report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg and Rest of Europe.

  • In Europe region, antibody-dependent cell-mediated cytotoxicity (ADCC) segment is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of rising demand of effective and safe treatment. Germany is dominating the European market owing to increasing demand of novel treatment for oncology diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rise in Expenditure in Healthcare Sector and Increase in Usage of Natural Killer (NK) Cell for the Treatment of Cancer and Infectious Diseases are boosting the Market Growth of Natural Killer (NK) Cell Therapeutics

Natural killer (NK) cell therapeutics market also provides you with detailed market analysis for every country growth in natural killer (NK) cell therapeutics industry with natural killer (NK) cell therapeutics drugs sales, impact of advancement in the natural killer (NK) cell therapeutics technology and changes in regulatory scenarios with their support for the natural killer (NK) cell therapeutics market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Natural Killer (NK) Cell Therapeutics Market Share Analysis

Natural killer (NK) cell therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Natural Killer (NK) Cell Therapeutics market.

The major companies which are dealing in the natural killer (NK) cell therapeutics market are Kiadis Pharma, EMERcell, Glycostem, Phio Pharmaceuticals, Bellicum Phamaceuticals, Inc., Affimed GmbH, multimmune GmbH, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., and Merck KGaA among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the natural killer (NK) cell therapeutics market.

For instance,

  • In July 2020, Fate Therapeutics signed a license agreement for off-the-shelf allogeneic NK cell products with Baylor College of Medicine. This agreement allowed the company to expand its platform of NK cell therapies, used for treatment of several kinds of diseases.
  • In April 2019, Kiadis Pharma signed an acquisition agreement with CytoSen Therapeutics, Inc., a company engaged in manufacturing of NK cell therapies. This acquisition helped the company to boost up its product pipeline NK cell therapies used for treatment of malignancies.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the natural killer (NK) cell therapeutics market which also provides the benefit for organization to improve their offering for natural killer (NK) cell therapeutics market.

Customization Available: Europe Natural Killer (NK) Cell Therapeutics Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, PIPELINE ANALYSIS

TABLE 2 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: EXPECTED PRODUCT LAUNCH DATE

TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)

TABLE 4 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2027 (USD MILLION)

TABLE 5 EUROPE NK CELL THERPAIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 6 EUROPE NK CELL DIRECTED ANTIBODIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2027 (USD MILLION)

TABLE 8 EUROPE ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 EUROPE BI-SPECIFIC ANTIBODIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 11 EUROPE CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 EUROPE CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 13 EUROPE HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 14 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 15 EUROPE HOSPITALS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 EUROPE SPECIALTY CLINICS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 EUROPE RESEARCH AND ACADEMIC INSTITUTES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 18 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 19 EUROPE HOSPITAL PHARMACIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 20 EUROPE DIRECT TENDER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 EUROPE OTHERS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 22 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 23 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 24 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 25 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 26 EUROPE CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 27 EUROPE HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 28 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 29 EUROPE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 30 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 31 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 32 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 33 GERMANY CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 34 GERMANY HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 35 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 36 GERMANY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 37 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 38 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 39 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 40 FRANCE CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 41 FRANCE HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 42 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 43 FRANCE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 44 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 45 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 46 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 47 ITALY CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 48 ITALY HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 49 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 50 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 51 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 52 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 53 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 54 U.K. CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 55 U.K. HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 56 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 57 U.K. NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 59 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 60 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 61 SPAIN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 62 SPAIN HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 63 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 64 SPAIN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 65 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 66 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 67 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 68 NETHERLANDS CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 69 NETHERLANDS HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 70 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 71 NETHERLANDS NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 72 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 73 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 74 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 75 RUSSIA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 76 RUSSIA HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 77 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 78 RUSSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 79 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 80 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 81 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 82 SWITZERLAND CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 83 SWITZERLAND HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 84 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 85 SWITZERLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 86 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 87 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 88 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 89 TURKEY CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 90 TURKEY HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 91 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 92 TURKEY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 93 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 94 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 95 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 96 AUSTRIA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 97 AUSTRIA HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 98 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 99 AUSTRIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 100 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 101 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 102 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 103 NORWAY CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 104 NORWAY HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 105 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 106 NORWAY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 107 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 108 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 109 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 110 HUNGARY CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 111 HUNGARY HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 112 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 113 HUNGARY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 114 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 115 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 116 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 117 LITHUANIA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 118 LITHUANIA HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 119 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 120 LITHUANIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 121 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 122 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 123 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 124 IRELAND CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 125 IRELAND HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 126 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 127 IRELAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 128 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 129 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 130 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 131 POLAND CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 132 POLAND HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 133 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 134 POLAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 135 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 136 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 137 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 138 LUXEMBOURG CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 139 LUXEMBOURG HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 140 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 141 LUXEMBOURG NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 142 ITALY NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions